Original Article
Copyright ©2010 Baishideng.
World J Hepatol. Jan 27, 2010; 2(1): 32-41
Published online Jan 27, 2010. doi: 10.4254/wjh.v2.i1.32
Table 1 Clinical and laboratory data of all studied cases (mean ± SD) n(%)
ParametersControlCHC without cirrhosisCHC with cirrhosisHCV-related HCC
(n = 15)(n = 50)(n = 30)(n = 30)
Age45.0 ± 7.547.4 ± 9.351.3 ± 5.948.9 ± 7.2
Male/female ratio2/17/32/12/1
Pallor0 (0)2 (4.0)5 (16.5)8 (26.6)
Jaundice0 (0)3 (6.0)6 (20.0)13 (43.3)
Palmer erythema0 (0)0 (0)15 (50.0)17 (56.6)
Spider naevi0 (0)0 (0)13 (43.3)16 (53.3)
Lower limb edema0 (0)0 (0)16 (53.3)10(33.3)
Child classification
A0 (0)50 (100)8 (26.6)1 (3.3)
B0 (0)9 (30.0)11 (36.6)
C0 (0)13 (43.3)18 (60.0)
ALT (IU/L)32.6 ± 4.263.2 ± 29.751.8 ± 4.378.1 ± 16.3
AST (IU/L)31.1 ± 5.149.1 ± 18.346.4 ± 5.168.3 ± 12.4
Albumin (g/dL)4.4 ± 0.53.80 ± 0.32.90 ± 0.72.80 ± 0.4
PT conc.97.6 ± 3.489.7 ± 5.853.4 ± 11.268.5 ± 3.8
Table 2 Immunohistochemical reactivity for Cyclin D1 in all studied cases (mean ± SE) n(%)
Groups n = 125Staining patternPositive expressionImmunohistochemical reactivity
Hepatic expression
Mild (< 5%)Moderate (5%-30%)Marked (> 30%)
Control (n = 15)Nuclear3 (20.0)3 (100)0 (0)0 (0)1.33 ± 0.33
CHC without cirrhosis (n = 50)Nuclear33 (66.0)25 (75.8)8 (24.2)0 (0)6.60 ± 0.72a
CHC with cirrhosis (n = 30)Nuclear21 (70.0)15 (71.4)6 (28.6)0 (0)9.95 ± 1.70ab
HCV-related HCC (n = 30)Nuclear30 (100)12 (40.0)12 (40.0)6 (20.0)19.85 ± 3.90abc
Well-differentiated HCC (n = 15)Nuclear15 (100)9 (60.0)6 (40.0)0 (0)10.10 ± 2.20ab
Poorly-differentiated HCC (n = 15)Nuclear15 (100)3 (20.0)6 (40.0)6 (40)31.60 ± 6.20abcd
Table 3 Immunohistochemical reactivity for cyclin E in patients with well-differentiated and poorly-differentiated (HCC) (mean ± SE) n(%)
GroupsPositive expressionImmunohistochemical reactivity
Stained cells
Mild < 5%Moderate 5%-49%Marked 50%-100%
Well-differentiated HCC (n = 15)6 (40.0)2 (33.3)4 (66.7)0 (0)25.3 ± 5.9
Poorly-differentiated HCC (n = 15)6 (40.0)0 (0)0 (0)6 (100)82.5 ± 2.1a
Table 4 Immunohistochemical reactivity for p21 in all studied cases (mean ± SE)
GroupsStaining patternHepatic expression
Control (n = 15)Nuclear1.5 ± 0.5
CHC without cirrhosis (n = 50)Nuclear6.5 ± 0.2a
CHC with cirrhosis (n = 30)Nuclear7.2 ± 0.8a
HCV-related HCC (n = 30)Nuclear4.9 ± 0.1ab
Well-differentiated HCC (n = 15)Nuclear5.6 ± 0.16
Poorly-differentiated HCC (n = 15)Nuclear4.2 ± 0.13
Table 5 Immunohistochemical reactivity for p27 in all studied cases (mean ± SE) n(%)
Groups n = 125Staining patternImmunohistochemical reactivity
Hepatic expression
Weak (< 50%)Marked (> 50%)
Control (n = 15)Nuclear/mixed9 (60.0)6 (40.0)44.4 ± 1.9
CHC without cirrhosis (n = 50)Nuclear/cytoplasmic5 (10.0)45 (90.0)59.8 ± 1.9a
CHC with cirrhosis (n = 30)Nuclear/mixed0 (0)30 (100)65.9 ± 1.6a
HCV-related HCC (n = 30)Nuclear/mixed21 (70.0)9 (30.0)34.1 ± 2.7abc
Well-differentiated HCC (n = 15)Nuclear7 (46.7)8 (53.3)36.2 ± 5.2abc
Poorly-differentiated HCC (n = 15)Mixed15 (100)0 (0)32.0 ± 1.7abc
Table 6 Immunohistochemical reactivity for Rb/p105 in all studied cases (mean ± SE) n(%)
Groups n = 125Staining patternPositive expressionImmunohistochemical reactivity
Hepatic expression
MildModerateMarked
(1%-30%)(31%-60%)(61%-100%)
Control (n = 15)Negative0 (0)0 (0)0 (0)0 (0)0.00 ± 0.00
CHC without cirrhosis (n = 50)Nuclear30 (60.0)27 (90.0)3 (10.0)0 (0)28.7 ± .1
CHC with cirrhosis (n = 30)Nuclear15 (50.0)5 (33.3)10 (66.7)0 (0)40.9 ± 2.8a
HCV-related HCC (n = 30)Nuclear21 (70.0)0 (0)12 (57.1)9 (42.9)61 ± 3.7ab
Well-differentiated HCC (n = 15)Nuclear12 (80.0)0 (0)12 (100)0 (0)67.3 ± 4.8ab
Poorly-differentiated HCC (n = 15)Nuclear9 (60.0)0 (0)0 (0)9 (100)55.7 ± 1.4abc
Table 7 Correlation analysis of different parameters in HCCs
ParameterHCV-related HCC
rP
Cyclin D1 # Cyclin E0.61< 0.01
Cyclin D1 # p21-0.51< 0.001
Cyclin D1 # p27-0.65< 0.001
Cyclin E # Rb/p1050.62< 0.01
Cyclin E # p21-0.64< 0.01
p21 # p270.47< 0.001
p21 # Rb/p105-0.42< 0.05